Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
July 27, Thursday 2017 3:55 AM       

       HEADLINES: Power outages across State on Wednesday evening                                              Dileep encroached govt land: Report                                              I’m a victim of gossip; I’ve no accounts that need to be probed: Namitha Pramod                                              Drunk doc smashes six vehicles                                              Those who blame me today will accept me tomorrow: A K Nazeer                                              Modi congratulates Nitish after resignation                                              80 per cent of Yemen children in need of immediate aid: UN                                              Syrian civilians fleeing IS in Raqa turn to smugglers                                              US Senate votes to begin debating Obamacare repeal                                              Galle Test: Dhawan, Pujara lead India's carnage on opening day                                              It's beginning of good times for Indian women's cricket: Mithali Raj                                              This year's Ashes could be Bodyline 2, says Damien Fleming                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Orbiting supermassive black holes discovered for first time  
Theweightmonitor.com launches mobile app for easier access to one-stop weight management platform  
New drug to treat blood cancer developed  
Threat of asteroid impact looming over Earth: experts  
Hottest known planet in universe discovered  
Wireless, battery-less pacemaker developed  
'Manned missions to Moon, Mars may face medical emergencies'  
Ransomware threat: Centre activates mechanism to prevent ‘Wannacry’ cyber attack  
2 lakh hit by 'unprecedented' cyberhack in 150 nations:Europol  
foodpanda revamps mobile app; provides more options  
ixigo launches trains app for Apple iOS users  
Virtual humans may help doctors learn empathy: study  
Gamers, here are five games to watch out for  
Yahoo India homepage gets brand new look  
Spacecraft flies between Saturn and rings in historic 1st  
Google targets 'fake news,' offensive search suggestions  
Offensive WhatsApp posts can land group admin in jail  
Facebook for 'everyone' and not just high end: Zuckerberg  
Google Earth re-invented for new era  
NASA images show how India looks from space at night  
Signs of life detected below world's deepest point  
'iPhones assembly in Bengaluru by Apple in less than a month'  
Five astronauts assigned to future ISS mission: NASA  
Trump plans to send humans to Mars  
First patient cured of rare blood disorder'  
 
Do you support Nitish Kumar's resignation as Bihar CM?
yes
 
no
 
don't know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy